SCHEMBL366568

SCHEMBL366568

O=C(O)c1cc(Br)c(F)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C4 P17516 2/20 0.47
AKR1C3 P42330 2/20 0.47
AKR1C2 P52895 2/20 0.47
AKR1C1 Q04828 2/20 0.47
KDM4E B2RXH2 3/20 0.44
ASPH Q12797 1/20 0.44
KDM8 Q8N371 1/20 0.44
PTPN1 P18031 3/20 0.42
KCNK2 O95069 1/20 0.42
KCNK10 P57789 1/20 0.42
TTR P02766 1/20 0.41
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
KEAP1 Q14145 2/20 0.39
NFE2L2 Q16236 1/20 0.39
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
DGAT1 O75907 1/20 0.39
PTPN2 P17706 1/20 0.39
PTPN6 P29350 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29705176 1.00 AKR1C4 (0.47) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL29851193 0.91 AKR1C4 (0.47) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL590353 0.91 AKR1C4 (0.47) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL24697741 0.88 KEAP1 (0.45) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL2371182 0.86 LCK (0.48) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL31430795 0.86 SMN1; SMN2 (0.48) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL6860298 0.86 SMN1; SMN2 (0.48) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL5872835 0.83 KDM4E (0.52) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL24760837 0.83 AKR1C2 (0.48) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL1976832 0.83 CA1 (0.45) AKR1C4AKR1C3AKR1C2AKR1C1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-109438214-B Preparation method of high-purity 5-bromo-2, 4-difluorobenzoic acid 大连奇凯医药科技有限公司 2021-06-11 CN claimed
US-20250091995-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. (JP) 2025-03-20 US disclosed
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 VIVIDION THERAPEUTICS, INC. 2025-02-20 US disclosed
US-20240360124-A1 Bromodomain Inhibitors ABBVIE INC. (US) 2024-10-31 US disclosed
US-20240254136-A1 COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS Redona Therapeutics, Inc. 2024-08-01 US disclosed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN disclosed
EP-4299563-A2 COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND Japan Tobacco Inc. (JP) 2024-01-03 EP disclosed
US-20230348363-A1 COMPOUNDS AND THEIR USE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-11-02 US disclosed
EP-4259605-A1 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE Astrazeneca AB (SE) 2023-10-18 EP disclosed
EP-3281939-B1 COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC (JP) 2023-10-18 EP disclosed
US-20090318702-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-12-24 US disclosed
US-7635704-B2 Stable crystal of 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2009-12-22 US disclosed
US-7635704-B2 Stable crystal of 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2009-12-22 US disclosed
US-7635704-B2 Stable crystal of 4-oxoquinoline compound JAPAN TOBACCO INC. (JP) 2009-12-22 US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 US disclosed
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND SHIONOGI & CO., LTD. (JP) 2009-02-05 US disclosed
EP-1636190-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND Japan Tobacco, Inc. (JP) 2006-03-22 EP disclosed
US-20060030710-A1 Stable crystal of 4-oxoquinoline compound SHIONOGI & CO., LTD. (JP) 2006-02-09 US disclosed
WO-2005113508-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND JAPAN TOBACCO INC. (JP) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250091995-A1 STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND KCNQ2, KCNQ1, KCNQ5 AKR1C4 2203/4885AKR1C3 2997/4885AKR1C2 2894/4885
US-20230348363-A1 COMPOUNDS AND THEIR USE RXFP1, RXFP3, RXFP2 AKR1C4 606/4885AKR1C3 534/4885AKR1C2 791/4885
US-20250059161-A1 COMPOUNDS AND METHODS FOR MODULATING STAT3 STAT3, JAK2, STAT1 AKR1C4 4611/4885AKR1C3 4583/4885AKR1C2 4382/4885
US-20090318702-A1 PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND CYP4X1, CYP3A4, CYP3A7 AKR1C4 307/4885AKR1C3 313/4885AKR1C2 677/4885
US-20090036684-A1 METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND IMPDH1, IMPDH2, CDK20 AKR1C4 952/4885AKR1C3 1096/4885AKR1C2 1590/4885
US-20060030710-A1 Stable crystal of 4-oxoquinoline compound KCNQ2, RCC1, SFPQ AKR1C4 3969/4885AKR1C3 4522/4885AKR1C2 4252/4885
US-20240254136-A1 COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS NSUN3, NSUN2, RBM3 AKR1C4 4450/4885AKR1C3 3818/4885AKR1C2 4055/4885
US-20240360124-A1 Bromodomain Inhibitors BRD4, BRD3, BRD1 AKR1C4 1493/4885AKR1C3 1156/4885AKR1C2 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.